Alectinib

Alectinib Reactions 1680, p21 - 2 Dec 2017 Acquired resistance to alectinib during treatment of AKK-positive lung tumour: case report A 51-year-old man had acquired resistance to alectinib treatment of during AKK-positive lung tumour with alectinib [dosage and route not stated]. The man, who had AKK-positive lung tumour, was started on first-line treatment with alectinib. However, he acquired resistance to alectinib in three months. Subsequently, the man was started on ceritinib or crizotinib, which showed only a moderate and temporary effect. Later, he died of unspecified reasons [outcome of reaction not stated]. Author comment: "However, acquired resistance to alectinib is inevitable" "The lung tumors acquired resistance to first-line treatment of alectinib in three months" Makimoto G, et al. A comprehensive analysis of autopsied specimens and patient derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib. Cancer Research 77 (Suppl. 13): abstr. 3164, Jul 2017. Available from: URL: http://doi.org/10.1158/1538-7445.AM2017-3164 [abstract] - Japan 803284842 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Alectinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/alectinib-P9RR20PMOi
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38952-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p21 - 2 Dec 2017 Acquired resistance to alectinib during treatment of AKK-positive lung tumour: case report A 51-year-old man had acquired resistance to alectinib treatment of during AKK-positive lung tumour with alectinib [dosage and route not stated]. The man, who had AKK-positive lung tumour, was started on first-line treatment with alectinib. However, he acquired resistance to alectinib in three months. Subsequently, the man was started on ceritinib or crizotinib, which showed only a moderate and temporary effect. Later, he died of unspecified reasons [outcome of reaction not stated]. Author comment: "However, acquired resistance to alectinib is inevitable" "The lung tumors acquired resistance to first-line treatment of alectinib in three months" Makimoto G, et al. A comprehensive analysis of autopsied specimens and patient derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib. Cancer Research 77 (Suppl. 13): abstr. 3164, Jul 2017. Available from: URL: http://doi.org/10.1158/1538-7445.AM2017-3164 [abstract] - Japan 803284842 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off